Share this post on:

Product Name :
Cadonilimab

Search keywords :
Cadonilimab

drugId :
null

Target Vo:
Programmed cell death protein 1

Target Vo Short Name :
PD-1

Moa_Name:
Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors

First Approval Country :
Mainland China

First Approval Date Filter:
2022

Origin Company_Name :
Zhongshan Akeso Biopharma Co Ltd

Active Company_Name :
Akesobio Australia Pty Ltd

Active Indication_Name:
Uterine Cervical Neoplasms

In Active Indication_Name:
Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
nNOS Antibody
Phospho-NF-KB p65 (Ser536) Antibody
Phospho-mTOR (Ser2448) Antibody (YA691): Phospho-mTOR (Ser2448) Antibody (YA691) is a non-conjugated and Mouse origined monoclonal antibody about 289 kDa, targeting to Phospho-mTOR (S2448). It can be used for WB,IHC assays with tag free, in the background of Human, Mouse.

Share this post on:

Author: Interleukin Related